The Stanford Genome Technology Center (SGTC), under the direction of Ronald W. Davis, PhD, has submitted several RO1 grant applications to NIH to continue and scale up several projects that OMF is funding. Below are descriptions of the newest proposals.
By Ronald W. Davis, PhD
We recently submitted two NIH R01 applications, one from Stanford (PI: Ron Davis) that focuses on the RBC deformability assay and one by Rahim Esfandyarpour from UC Irvine on developing the nanoneedle for higher throughput. Both grants are using the OMF-funded patient sample collection and processing done at the SGTC under a Stanford IRB approved protocol. They are an extension of the foundational work that has been funded by OMF. Rahim’s work is also using an OMF-funded nanoneedle engineer/technician. Both applications seek to test a much higher number of samples from well-diagnosed ME/CFS patients as well as healthy controls and patients with autoimmune diseases such as MS. They both also propose to explore the underlying biology of the ME/CFS-specific difference that each assay is measuring. In addition to these two R01 submissions, Laurel Crosby has also submitted an NIH shared instrumentation grant for a new device that can assay mitochondrial function in white blood cells at very high throughput. This latter grant is in addition to her February submission this year of an R21 exploratory grant that will investigate the impact of organic mercury exposure on selenium bioavailability in ME/CFS.